ImmunoGen (NASDAQ: IMGN)
Some price data may be temporarily unavailable.
ImmunoGen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ImmunoGen Company Info
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
News & Analysis
20 High-Yield Dividend Stocks to Buy in 2024
A list of high-yielding dividend stocks to consider buying now.
Why ImmunoGen Stock Is Soaring Wednesday
The company released trial data on its lead therapy, Elahere, designed to treat ovarian cancer.
Why Shares of ImmunoGen Jumped Friday
The biotech company's first-quarter report had plenty of good news.
Is ImmunoGen Stock a Bargain After Dropping 39%?
It takes more than a price drop to make a bargain.
Why Shares of ImmunoGen Jumped 20.3% in December
The biotech company that focuses on oncology drugs released news from a positive clinical trial regarding its lead drug.
3 Under-the-Radar Biotech Stocks to Buy in 2022
They may deliver major gains down the road.
Why ImmunoGen Stock Is Flying High Today
The biotech is continuing to surge after after a late-stage win in treatment for advanced ovarian cancer.
Why ImmunoGen Stock Soared Today
The cancer-fighting specialist's new antibody treatment could be a gamechanger.
Valuation
Earnings Transcripts
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript
IMGN earnings call for the period ending June 30, 2022.
ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript
IMGN earnings call for the period ending March 31, 2022.
ImmunoGen (IMGN) Q4 2021 Earnings Call Transcript
IMGN earnings call for the period ending December 31, 2021.
ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript
IMGN earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.